Besides the well-known poly(ADP-ribose) polymerase (PARP) inhibitors to target BRCA1/2-deficient cancers [6], preclinical studies have shown that defects in ATM, BRCA1/2, and TP53 confer sensitivity to ATR inhibition in tumor cells [7–10]. Here, ATR is linked to neoplasm.